

## PRODUCT INFORMATION

<b>Clone ID</b>	163D11
<b>Target</b>	GPC3
<b>Synonyms</b>	DGSX;GTR2-2;MXR7;OCI-5;SDYS;SGB;SGBS;SGBS1
<b>Host Species</b>	Rabbit
<b>Description</b>	PE-conjugated Anti-GPC3 antibody(163D11), IgG1 Chimeric mAb
<b>Delivery</b>	Under Development
<b>Uniprot ID</b>	P51654
<b>IgG type</b>	Rabbit/Human Fc chimeric IgG1
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	Human
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Liquid□PBS with 0.05% Proclin300, 1% BSA
<b>Storage &amp; Shipping</b>	Store at 2°C-8°C for 6 months

## Background

Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behme syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009] References□ Fu Ying,Urban Daniel J,Nani Roger R et al. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.[J] .Hepatology, 2019, 70: 563-576. Zhang Yi-Fan,Ho Mitchell,Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.[J] .Sci Rep, 2016, 6: 33878.

**Usage** Research use only

**Conjugate** PE-conjugated

## DIMA Disclaimer

All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

